{
    "clinical_study": {
        "@rank": "144768", 
        "arm_group": [
            {
                "arm_group_label": "DS-1971", 
                "arm_group_type": "Experimental", 
                "description": "single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo matching each of the DS-1971 dosages."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, double-blind, placebo-controlled and ascending single dose study. It\n      is hypothesised that single oral doses of DS-1971a within the planned dose range will be\n      safe and well tolerated by healthy male subjects."
        }, 
        "brief_title": "Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects aged 18-45 years.\n\n          -  A body mass index (BMI or Quetlet index) in the range 18-30 kg/m^2, inclusive, and\n             weighing between 50 and 100 kg at screening.\n\n        Body Mass Index (BMI) =weight[kg] / (height [m])^2\n\n          -  Willing to use a reliable method of contraception and not donate sperm during the\n             study, and for 4 months afterwards.\n\n          -  Sufficient intelligence to understand the nature of the study and any hazards of\n             participating in it.  Ability to communicate satisfactorily with the Investigator and\n             to participate in, and comply with requirements of, the entire study.\n\n          -  Willing to give written consent to participate in the study after reading the ICF,\n             and after having the opportunity to discuss the study with the Investigator or his\n             delegate.\n\n          -  Willing to give written consent to have his data entered into The Over-volunteering\n             Prevention System.\n\n        Exclusion Criteria:\n\n          -  Clinically relevant abnormal history, physical findings, ECG findings, or laboratory\n             values that could interfere with the objectives of the study or compromise the safety\n             of the subject.\n\n          -  Presence or history of acute or chronic illness, including (but not limited to) liver\n             or kidney disease, hypertension, seizures, or any known impairment of endocrine, or\n             other specific body-organ dysfunction.\n\n          -  History of serious reaction to any medicine.\n\n          -  Presence or history of malignant disease.\n\n          -  Acute or chronic infectious disease, including HIV, HBV or HCV infection.\n\n          -  Surgery (e.g. stomach bypass) or medical condition that might affect how the body\n             handles or absorbs medicines.\n\n          -  Significant illness within 4 weeks before the dose of trial medication.\n\n          -  Participation in another clinical trial of a new chemical entity or a prescription\n             medicine within the previous 3 months, or unwilling to abstain from participating in\n             other clinical trials during the study and for 3 months after receipt of trial\n             medication.\n\n          -  Abnormal ECG waveform morphology at screening that would preclude accurate\n             measurement of the QT interval duration.\n\n          -  QTcF interval duration > 430 msec, obtained as an average from the 3 ECG measurements\n             on the triplicate screening ECGs.\n\n          -  Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m^2MDRD] equation).\n\n          -  Use of any prescription or OTC medications known to be strong inhibitors or strong\n             inducers of CYP enzymes (also known as CYP P450 enzymes) during the 30 days before\n             the dose of trial medication; use of any other prescription or OTC medicine including\n             vitamins or herbal remedies like St John's wort, with the exception of acetaminophen\n             (paracetamol), during the 7 days before the dose of trial medication.\n\n          -  Consumption of grapefruit, grapefruit juice or Seville oranges within 10 days before\n             the dose of trial medication, or unwilling to abstain from consuming them throughout\n             the study.\n\n          -  Consumption of food or beverages containing caffeine or xanthine within 24 h before\n             admission on Day -1, or unwilling to abstain from consuming them for 3 days after\n             receiving the trial medication.\n\n          -  Loss of more than 400 mL blood during the 3 months before the study.\n\n          -  Donation of blood, plasma, platelets, or any other blood components during the 3\n             months before the study, or unwilling to abstain from doing so during the study and\n             for 3 months after receipt of trial medication.\n\n          -  Abuse of drugs or alcohol during the 2 years before the dose of trial medication, or\n             intake of more than 21 units of alcohol weekly.\n\n          -  Use of tobacco products or nicotine-containing products during the 3 months before\n             the dose of trial medication.\n\n          -  Evidence of drug or alcohol abuse at screening or admission.\n\n          -  Likely possibility that the volunteer will not cooperate with the requirements of the\n             protocol.\n\n          -  Objection by GP to the volunteer entering the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107885", 
            "org_study_id": "DS1971-A-E101"
        }, 
        "intervention": [
            {
                "arm_group_label": "DS-1971", 
                "description": "6 subjects in each group will receive DS-1971.", 
                "intervention_name": "DS-1971", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "2 subjects in each group will receive placebo.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "recruit@hmrlondon.com", 
                "last_name": "Recruit HMR-London"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "Hammersmith Medicines Research Ltd."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Double-blind, Randomized, Placebo-controlled Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "determine number, type, and severity of adverse events", 
                "measure": "safety and tolerability adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "20 days after dose"
            }, 
            {
                "description": "determine adverse changes in vital signs, ECG.", 
                "measure": "safety and tolerability physical exam", 
                "safety_issue": "Yes", 
                "time_frame": "20 days after dose"
            }, 
            {
                "description": "determine adverse changes in laboratory safety tests of blood (biochemistry and haematology) and urine.", 
                "measure": "safety and tolerability laboratory blood and urine tests", 
                "safety_issue": "Yes", 
                "time_frame": "from day 1 through 20 days after dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "concentration in blood measured as Area under the curve (AUC)", 
                "measure": "plasma concentration AUC", 
                "safety_issue": "No", 
                "time_frame": "day 4"
            }, 
            {
                "description": "Cmax", 
                "measure": "maximum blood concentration", 
                "safety_issue": "No", 
                "time_frame": "day 4"
            }, 
            {
                "description": "T_max", 
                "measure": "time of maximum blood concentration", 
                "safety_issue": "No", 
                "time_frame": "day 4"
            }, 
            {
                "description": "T_1/2", 
                "measure": "half-life of drug in body", 
                "safety_issue": "No", 
                "time_frame": "day 4"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}